Pre-made Indatuximab benchmark antibody ( Whole mAb ADC, anti-SDC1 therapeutic antibody, Anti-SDC/CD138/SYND1/syndecan Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-271

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-271 Category Tag

Product Details

Pre-Made Indatuximab biosimilar, Whole mAb ADC, Anti-SDC1 Antibody: Anti-SDC/CD138/SYND1/syndecan therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

Products Name (INN Index)

Pre-Made Indatuximab biosimilar, Whole mAb ADC, Anti-SDC1 Antibody: Anti-SDC/CD138/SYND1/syndecan therapeutic antibody

INN Name

Indatuximab

Target

SDC1

Format

Whole mAb ADC

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2011

Companies

Biotest AG

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Bladder cancer,Breast cancer,Multiple myeloma

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

SDC1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide